cefotaxime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	546	63527-52-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefotaxime cefotaxime sodium cephotaxime cefotaxime sodium salt	Semisynthetic broad-spectrum cephalosporin. Molecular weight: 455.46 Formula: C16H17N5O7S2 CLOGP: 0.33 LIPINSKI: 1 HAC: 12 HDO: 3 TPSA: 173.51 ALOGS: -3.49 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefotaxime
cefotaxime sodium
cephotaxime
cefotaxime sodium salt

Semisynthetic broad-spectrum cephalosporin.

Molecular weight: 455.46
Formula: C16H17N5O7S2
CLOGP: 0.33
LIPINSKI: 1
HAC: 12
HDO: 3
TPSA: 173.51
ALOGS: -3.49
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
4	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	30 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	376.38 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.19 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.60 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
March 11, 1981	FDA	SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	199.82	26.88	81	4607	28343	50572093
Hepatocellular injury	101.36	26.88	49	4639	25898	50574538
Eosinophilia	87.56	26.88	40	4648	18612	50581824
Premature baby	85.06	26.88	39	4649	18298	50582138
Toxic epidermal necrolysis	77.04	26.88	38	4650	20954	50579482
Rash maculo-papular	65.77	26.88	37	4651	26604	50573832
Pyrexia	64.35	26.88	121	4567	380082	50220354
Septic shock	63.29	26.88	48	4640	57127	50543309
Patent ductus arteriosus	61.09	26.88	20	4668	3800	50596636
Acute generalised exanthematous pustulosis	57.69	26.88	24	4664	8914	50591522
Laryngeal stenosis	54.31	26.88	13	4675	784	50599652
Purpura	52.05	26.88	23	4665	9888	50590548
Foetal exposure during pregnancy	49.25	26.88	31	4657	27328	50573108
Umbilical erythema	47.89	26.88	8	4680	72	50600364
Fatigue	45.59	26.88	6	4682	707595	49892841
Agranulocytosis	45.54	26.88	27	4661	21394	50579042
Hydrocephalus	45.46	26.88	17	4671	4771	50595665
Necrosis	42.01	26.88	16	4672	4720	50595716
Encephalopathy	38.82	26.88	29	4659	33682	50566754
Subperiosteal abscess	37.97	26.88	5	4683	5	50600431
Thrombocytopenia	35.52	26.88	51	4637	127622	50472814
Ventricular dysfunction	35.06	26.88	12	4676	2609	50597827
Lactic acidosis	34.68	26.88	27	4661	33328	50567108
Multiple organ dysfunction syndrome	34.38	26.88	32	4656	50305	50550131
Acute kidney injury	34.04	26.88	69	4619	227989	50372447
Death neonatal	33.53	26.88	7	4681	225	50600211
Toxic shock syndrome streptococcal	32.79	26.88	6	4682	95	50600341
Haemophagocytic lymphohistiocytosis	32.76	26.88	16	4672	8617	50591819
Stenotrophomonas infection	31.86	26.88	10	4678	1659	50598777
Cholestasis	31.83	26.88	23	4665	25378	50575058
Pulmonary necrosis	31.76	26.88	6	4682	114	50600322
Central nervous system necrosis	30.88	26.88	6	4682	133	50600303
Cross sensitivity reaction	30.23	26.88	10	4678	1959	50598477
Petechiae	29.84	26.88	17	4671	12495	50587941
Oligohydramnios	29.08	26.88	13	4675	5737	50594699
Hepatic failure	29.02	26.88	24	4664	32259	50568177
Hyperleukocytosis	28.70	26.88	7	4681	457	50599979
Respiratory acidosis	28.49	26.88	13	4675	6015	50594421
Disseminated intravascular coagulation	27.33	26.88	18	4670	17117	50583319
Brain abscess	27.12	26.88	9	4679	1782	50598654

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	295.03	25.04	132	5650	27860	29540885
Rash maculo-papular	151.17	25.04	80	5702	24209	29544536
Hepatocellular injury	143.71	25.04	74	5708	21169	29547576
Eosinophilia	104.94	25.04	61	5721	22100	29546645
Toxic epidermal necrolysis	80.74	25.04	48	5734	18105	29550640
Agranulocytosis	56.43	25.04	40	5742	20300	29548445
Acute kidney injury	55.67	25.04	144	5638	265123	29303622
Haemophagocytic lymphohistiocytosis	55.27	25.04	31	5751	10473	29558272
Toxic skin eruption	54.64	25.04	30	5752	9727	29559018
Clostridium difficile colitis	53.73	25.04	33	5749	13179	29555566
Cholestasis	49.16	25.04	39	5743	23423	29545322
Urethral valves	47.28	25.04	11	5771	272	29568473
Purpura	45.21	25.04	26	5756	9206	29559539
Thrombotic microangiopathy	41.32	25.04	24	5758	8657	29560088
Pyrexia	38.24	25.04	133	5649	287489	29281256
Neutropenia	37.84	25.04	81	5701	131630	29437115
Klebsiella infection	36.79	25.04	21	5761	7328	29561417
Mixed liver injury	32.64	25.04	13	5769	2038	29566707
Haematoma muscle	29.98	25.04	10	5772	947	29567798
Nausea	29.41	25.04	10	5772	289245	29279500
ADAMTS13 activity decreased	29.22	25.04	6	5776	81	29568664
Rash	28.90	25.04	92	5690	189727	29379018
Systemic candida	28.83	25.04	13	5769	2767	29565978
Septic shock	28.61	25.04	47	5735	62513	29506232
Respiratory gas exchange disorder	28.33	25.04	8	5774	433	29568312
Death	28.22	25.04	16	5766	342068	29226677
Red blood cell schistocytes present	28.03	25.04	7	5775	235	29568510
Thrombocytopenia	27.91	25.04	73	5709	134750	29433995
Fatigue	27.32	25.04	14	5768	316807	29251938
Bicytopenia	27.07	25.04	11	5771	1816	29566929
Hepatic cytolysis	26.87	25.04	18	5764	8329	29560416
Drug ineffective	26.47	25.04	140	5642	363030	29205715
Gamma-glutamyltransferase increased	25.97	25.04	29	5753	26708	29542037
Vasculitis necrotising	25.84	25.04	8	5774	597	29568148
Face oedema	25.71	25.04	19	5763	10264	29558481
Acute generalised exanthematous pustulosis	25.42	25.04	15	5767	5568	29563177

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms	488.28	22.04	208	8919	54009	64435596
Hepatocellular injury	235.90	22.04	119	9008	45116	64444489
Rash maculo-papular	220.01	22.04	115	9012	46911	64442694
Eosinophilia	197.98	22.04	100	9027	37976	64451629
Toxic epidermal necrolysis	154.35	22.04	84	9043	37082	64452523
Agranulocytosis	104.71	22.04	66	9061	38163	64451442
Purpura	97.55	22.04	48	9079	17198	64472407
Pyrexia	94.87	22.04	229	8898	558415	63931190
Acute kidney injury	82.48	22.04	190	8937	449050	64040555
Toxic skin eruption	78.38	22.04	43	9084	19241	64470364
Cholestasis	72.39	22.04	56	9071	44816	64444789
Septic shock	67.82	22.04	79	9048	105358	64384247
Clostridium difficile colitis	64.68	22.04	43	9084	27180	64462425
Fatigue	62.08	22.04	15	9112	748715	63740890
Acute generalised exanthematous pustulosis	61.73	22.04	33	9094	14025	64475580
Thrombocytopenia	57.72	22.04	109	9018	223692	64265913
Haemophagocytic lymphohistiocytosis	57.40	22.04	34	9093	17575	64472030
Neutropenia	53.68	22.04	110	9017	239514	64250091
Encephalopathy	51.70	22.04	52	9075	58767	64430838
Laryngeal stenosis	48.68	22.04	13	9114	794	64488811
Pseudomembranous colitis	44.55	22.04	19	9108	4897	64484708
Cross sensitivity reaction	44.26	22.04	17	9110	3350	64486255
Pain	44.06	22.04	12	9115	553499	63936106
Thrombotic microangiopathy	43.69	22.04	28	9099	16627	64472978
Nausea	43.59	22.04	29	9098	785771	63703834
Mixed liver injury	42.57	22.04	19	9108	5462	64484143
Dermatitis bullous	38.57	22.04	23	9104	12031	64477574
Hepatic cytolysis	37.80	22.04	24	9103	14025	64475580
Multiple organ dysfunction syndrome	33.34	22.04	55	9072	101358	64388247
Hyperbilirubinaemia	33.17	22.04	26	9101	21179	64468426
Hydrocephalus	31.04	22.04	17	9110	7574	64482031
Arthralgia	30.91	22.04	12	9115	442248	64047357
Anaphylactic shock	30.73	22.04	29	9098	30299	64459306
Bicytopenia	29.55	22.04	13	9114	3609	64485996
Klebsiella infection	29.19	22.04	20	9107	13261	64476344
Red blood cell schistocytes present	29.14	22.04	8	9119	542	64489063
Subperiosteal abscess	28.56	22.04	5	9122	38	64489567
Hepatic failure	28.30	22.04	37	9090	55357	64434248
Ventricular dysfunction	27.81	22.04	14	9113	5256	64484349
ADAMTS13 activity decreased	27.47	22.04	6	9121	155	64489450
Haematoma muscle	27	22.04	10	9117	1783	64487822
Respiratory gas exchange disorder	26.53	22.04	8	9119	757	64488848
Brain oedema	26.06	22.04	23	9104	22052	64467553
Stevens-Johnson syndrome	25.99	22.04	28	9099	34221	64455384
Neutrophil count increased	25.37	22.04	24	9103	25150	64464455
Rash	24.76	22.04	129	8998	458420	64031185
Gamma-glutamyltransferase increased	24.16	22.04	32	9095	48478	64441127
CD4 lymphocytes increased	24.14	22.04	6	9121	275	64489330
Central nervous system necrosis	24.08	22.04	6	9121	278	64489327
Vasculitis necrotising	23.88	22.04	8	9119	1064	64488541
Enterococcal infection	23.87	22.04	18	9109	13848	64475757
HIV associated nephropathy	23.73	22.04	6	9121	295	64489310
Erythema	23.68	22.04	69	9058	187001	64302604
Mucormycosis	23.46	22.04	14	9113	7327	64482278
Hyperlactacidaemia	23.04	22.04	12	9115	4832	64484773
CNS ventriculitis	22.95	22.04	6	9121	337	64489268

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DD01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
ATC	J01DD51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Third-generation cephalosporins
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:88188	allergenic drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Streptococcal meningitis	indication	4510004	DOID:11574
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Streptococcal septicemia	indication	29577008
Pneumonia due to Streptococcus	indication	34020007
Neonatal conjunctivitis	indication	34298002	DOID:9699
Pneumonia due to Pseudomonas	indication	41381004
Bacterial arthritis	indication	48245008
Peritonitis	indication	48661000
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Haemophilus influenzae pneumonia	indication	70036007
Bacterial infection due to Serratia	indication	71120004
Septicemia due to Serratia	indication	82091000
Bacterial meningitis	indication	95883001	DOID:9470
Infection of bone	indication	111253001
Female genital tract infection	indication	125585007
Infectious disease of abdomen	indication	128070006
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Meningococcal meningitis	indication	192644005
Escherichia coli meningitis	indication	192655005
Proteus pneumonia	indication	195888009
Sepsis of the newborn	indication	206376005
Neonatal pneumonia	indication	233619008
Neonatal meningitis	indication	276674008
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Bacterial urinary infection	indication	312124009
Meningitis due to Klebsiella mobilis	indication	420585007
Sepsis due to Staphylococcus aureus	indication	448417001
Cesarean Section Infection Prevention	indication
Streptococcal Peritonitis	indication
E. Coli Peritonitis	indication
E. Coli Endometritis	indication
Haemophilus Influenzae Type B Infections	indication
Neonatal Group B Streptococcal Septicemia	indication
Klebsiella Endometritis	indication
Proteus Endometritis	indication
Enterococcus Pelvic Cellulitis	indication
Prevention of Perioperative Infection	indication
Proteus Mirabilis Osteomyelitis	indication
Bacteroides Pelvic Cellulitis	indication
Klebsiella Pelvic Inflammatory Disease	indication
Staphylococcus Endometritis	indication
H. Influenzae Meningitis	indication
Clostridium Pelvic Inflammatory Disease	indication
Haemophilus Parainfluenzae Pneumonia	indication
Bacteroides Pelvic Inflammatory Disease	indication
Staphylococcus Pelvic Inflammatory Disease	indication
Proteus Peritonitis	indication
Clostridium Endometritis	indication
Staphylococcus Epidermidis Urinary Tract Infection	indication
Enterococcus Pelvic Inflammatory Disease	indication
Morganella Morganii Urinary Tract Infection	indication
Fusobacterium Pelvic Inflammatory Disease	indication
Streptococcus Osteomyelitis	indication
Enterococcus Urinary Tract Infection	indication
Clostridium Pelvic Cellulitis	indication
Serratia Urinary Tract Infection	indication
Enterobacter Pneumonia	indication
Enterobacter Pelvic Inflammatory Disease	indication
Bacteroides Endometritis	indication
Providencia Urinary Tract Infection	indication
Citrobacter Urinary Tract Infection	indication
Fusobacterium Endometritis	indication
Proteus Pelvic Inflammatory Disease	indication
Clostridium Peritonitis	indication
Staphylococcus Aureus Urinary Tract Infection	indication
E. Coli Pelvic Inflammatory Disease	indication
E. Coli Pelvic Cellulitis	indication
Enterobacter Endometritis	indication
Pseudomonas Aeruginosa Urinary Tract Infection	indication
Klebsiella Pneumoniae Peritonitis	indication
Enterococcus Endometritis	indication
Pyrexia of unknown origin	off-label use	7520000
Acute gonococcal cervicitis	off-label use	20943002	DOID:10615
Lyme disease	off-label use	23502006	DOID:11729
Acute gonococcal urethritis	off-label use	29864006
Lyme arthritis	off-label use	33937009
Pseudotuberculosis	off-label use	36753006
Gonorrhea of rectum	off-label use	42746002
Lyme carditis	off-label use	77863005
Infection by Yersinia enterocolitica	off-label use	80960004
Ventilator-acquired pneumonia	off-label use	429271009
Disseminated Gonococcal Infection	off-label use
Lyme Disease of the Central Nervous System	off-label use
Acute nephropathy	contraindication	58574008
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.39	acidic
pKa2	13.31	acidic
pKa3	3.1	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Peptidoglycan synthase FtsI	Enzyme	FTSI_ECOLI	INHIBITOR	IC50	6.24	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1A	Enzyme	PBPA_ECOLI	INHIBITOR	IC50	6.51	WOMBAT-PK	CHEMBL
Penicillin-binding protein 1B	Enzyme	PBPB_ECOLI	INHIBITOR	IC50	5.66	WOMBAT-PK	CHEMBL
Penicillin-binding protein 2	Enzyme	PBP2_ECOLI	INHIBITOR	IC50	4.62	WOMBAT-PK	CHEMBL
Beta-lactamase	Enzyme	B2ZTR6_ACIBA		Ki	6.30	CHEMBL
Beta-lactamase	Enzyme	D6NSM8_ACIBA		Ki	5.60	CHEMBL

External reference:

ID	Source
4019663	VUID
N0000147755	NUI
D00919	KEGG_DRUG
64485-93-4	SECONDARY_CAS_RN
203117	RXNORM
4018466	VANDF
4019663	VANDF
C0007554	UMLSCUI
CHEBI:3498	CHEBI
CE3	PDB_CHEM_ID
CHEMBL1010	ChEMBL_ID
CHEMBL1730	ChEMBL_ID
D002439	MESH_DESCRIPTOR_UI
DB00493	DRUGBANK_ID
10893	IUPHAR_LIGAND_ID
4504	INN_ID
N2GI8B1GK7	UNII
5742673	PUBCHEM_CID
42787	MMSL
4378	MMSL
d00008	MMSL
002727	NDDF
004845	NDDF
3334000	SNOMEDCT_US
372704003	SNOMEDCT_US
41722006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9930	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9931	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9933	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9935	INJECTION	10 g	INTRAVENOUS	ANDA	24 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	21586-011	POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	Unapproved drug for use in drug shortage	2 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	21586-012	POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	Unapproved drug for use in drug shortage	2 sections
CEFOTAXIME	HUMAN PRESCRIPTION DRUG LABEL	1	55648-947	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	11 sections
CEFOTAXIME	HUMAN PRESCRIPTION DRUG LABEL	1	55648-948	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	11 sections
CEFOTAXIME	HUMAN PRESCRIPTION DRUG LABEL	1	55648-986	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	11 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	64679-947	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	20 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	64679-948	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAMUSCULAR	ANDA	20 sections
Cefotaxime	HUMAN PRESCRIPTION DRUG LABEL	1	64679-986	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	20 sections